X0609 4 2026-08-17 0001070081 PTC THERAPEUTICS, INC. PTCT 0001578852 Boulding Mark Elliott false C/O PTC THERAPEUTICS, INC. 500 WARREN CORPORATE CENTER DRIVE WARREN NJ 07059 false true false false EXEC. VP AND CLO 1 Common Stock 2026-08-17 4 M 0 2813 25.69 A 108085 D Common Stock 2026-08-17 4 S 0 1844 72.39 D 106241 D Common Stock 2026-08-17 4 S 0 969 72.90 D 105272 D Stock Option (Right to Buy) 25.69 2026-08-17 4 M 0 2813 0 D 2034-02-14 Common Stock 2813 16876 D This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $71.72 to $72.67 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $72.73 to $73.02 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. /s/ Avraham S. Adler, Attorney-in-Fact 2026-08-19